TKT and hepatocellular carcinoma: To further explore the potential role of TKT in immunotherapy, we subsequently analyzed TKT expression in HCC samples from patients treated with nivolumab (PD-1 inhibitor) and cabozantinib (a multi-targeted tyrosine kinase inhibitor), using the GSE238264 dataset.